文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

美国前列腺癌大分割放疗实施情况:国家癌症数据库分析

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis.
PubMed 文献 · Pract Radiat Oncol · 2017-01-01

该研究基于美国国家癌症数据库,分析2004至2013年接受外照射放疗的132403例局限期前列腺癌患者,发现大分割放疗使用率从6.2%升至14.2%,其中极端大分割增幅最大,且使用与年轻、低危、非黑人种族、非医疗补助保险、学术机构等因素独立相关。

要点

  • 大分割放疗使用率从2004年6.2%增至2013年14.2%,以极端大分割增长为主。
  • 极端大分割从0.3%升至8.5%,中度大分割基本不变(5.9%至5.7%)。
  • 大分割使用与年轻、低危、非黑人种族、非医疗补助保险、学术机构等因素独立相关。

核心结论

  • 常规分割仍是局限期前列腺癌最常见放疗方案,但大分割使用率因极端大分割增加而上升。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性分析,纳入2004至2013年接受外照射放疗的局限期(N0,M0)前列腺癌男性132403例。

主要发现

  • 132403例中,常规分割120055例,中度大分割7264例,极端大分割5084例。
  • 大分割总使用率从2004年6.2%升至2013年14.2%(P < .01)。
  • 极端大分割从0.3%升至8.5%,中度大分割从5.9%至5.7%基本不变。
  • 大分割使用独立相关因素包括年轻、诊断年份较晚、非黑人种族、非医疗补助保险、非西部居住、较高收入、学术治疗机构、距治疗机构距离较远、低危疾病组(NCCN标准)及未接受激素治疗。

关键数值与推荐

  • 常规分割定义为每次剂量≤2.0 Gy,中度大分割为>2.0但<5.0 Gy,极端大分割为≥5.0 Gy。
  • 排除每次剂量<1.5或>15.0 Gy者,以及总剂量<25或>90 Gy者。

临床怎么用

  • 财务和后勤因素可能加速短疗程方案的采用。
  • 鉴于组间存在多个人口学和预后差异,需要比较极端大分割与替代方案的随机结局数据。

局限性

  • 本研究为基于国家癌症数据库的回顾性分析,未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preclinical and clinical research over the past several decades suggests that hypofractionated (HFxn) radiation therapy schedules produce similar treatment outcomes compared with conventionally fractionated (CFxn) radiation therapy for definitive treatment of localized prostate cancer (PCa). We sought to evaluate national trends and identify factors associated with HFxn utilization using the US National Cancer Database. METHODS AND MATERIALS: We queried the National Cancer Database for men diagnosed with localized (N0,M0) PCa from 2004 through 2013 treated with external beam radiation therapy. Patients were grouped by dose per fraction (DpF) in Gray: CFxn was defined as DpF ≤2.0, moderate HFxn as DpF >2.0 but <5.0, and extreme HFxn as DpF ≥5.0. Men receiving DpF <1.5 or >15.0 were excluded, as were those receiving <25 or >90 Gy total dose. Multiple logistic regression was performed to identify demographic, clinical, and treatment factor associations. RESULTS: A total of 132,403 men were identified, with 120,055 receiving CFxn, 7264 moderate HFxn, and 5084 extreme HFxn. Although CFxn was by far the most common approach over the analysis period, HFxn use increased from 6.2% in 2004 to 14.2% in 2013 (P < .01). Extreme HFxn use increased the most (from 0.3% to 8.5%), whereas moderate HFxn utilization was unchanged (from 5.9% to 5.7%). HFxn use was independently associated with younger age, later year of diagnosis, non-black race, non-Medicaid insurance, non-Western residence, higher income, academic treatment facility, greater distance from treatment facility, low-risk disease group (by National Comprehensive Cancer Network criteria), and nonreceipt of hormone therapy. CONCLUSIONS: Although CFxn remains the most common radiation therapy schedule for localized PCa, use of HFxn appears to be increasing in the United States as a result of increased extreme HFxn use. Financial and logistical factors may accelerate adoption of shorter schedules. Considering the multiple demographic and prognostic differences identified between these groups, randomized outcome data comparing extreme HFxn to alternatives are desirable.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stokes WA, Kavanagh BD, Raben D, et al. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol. 2017. PMID: 28673554. doi:10.1016/j.prro.2017.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。